FDA Clears Takeda’s Mimrylo for Polycythemia Vera, Introducing a Novel Treatment Option

As reported on MedCity News, the U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare…

Continue Reading FDA Clears Takeda’s Mimrylo for Polycythemia Vera, Introducing a Novel Treatment Option

BioNTech Ends Phase 2 Trial of Personalized mRNA Therapy in High-Risk Colorectal Cancer

As reported on Drugs, BioNTech has decided to halt development of its Phase 2 BNT122-01 study investigating autogene cevumeran (BNT122/RO7198457) in patients with resected colorectal cancer who remained ctDNA-positive after…

Continue Reading BioNTech Ends Phase 2 Trial of Personalized mRNA Therapy in High-Risk Colorectal Cancer